Seminal suPAR levels as marker of Abacterial male accessory gland inflammation in Hypogonadism

Domenico Milardi, Giuseppe Grande, Chiara Autilio, Francesca Mancini, Laura De Marinis, Riccardo Marana, Cecilia Zuppi, Andrea Urbani, Alfredo Pontecorvi, Silvia Baroni

Research output: Contribution to journalArticle

Abstract

Background: Recent evidences suggest that hypogonadism is an important risk factor for lower urinary tract symptoms and benign prostatic hyperplasia. Several papers have discussed the role of chronic inflammation in the development of BPH, which may be modulated by the hypogonadal state. Soluble Urokinase-type Plasminogen Activator Receptor (suPAR), known protein marker of systemic inflammation, can be assayed in the seminal plasma and represents a reliable and sensitive marker of inflammation for the Male Accessory Gland Inflammation (MAGI). Objective: The aim of this study has been to investigate if seminal suPAR is elevated in MAGI with hypogonadism and if suPAR represent a useful marker of abacterial inflammation in hypogonadism. Methods: We included in the study twenty male patients aged between 25 and 55 year-old with secondary postsurgical hypogonadism. The same patients were also evaluated after a 3-month of Testosterone Replacement Therapy (TRT), to evaluate the effect of androgen replacement therapy on suPAR. Ten fertile men have been enrolled as a control group in the protocol. SuPAR concentrations were assayed on seminal plasma using an Enzyme-Linked Immunosorbent Assay (ELISA) kit. Results: Hypogonadic patients presented significantly increased levels of seminal suPAR respect to controls (86.1±36.8 vs 55.2±20.0 ng/mL, p<0.05). TRT in hypogonadic patients has been associated with a significant reduction of suPAR levels as reported in the control group (50.9±22.91 vs 86.1±36.8 ng/ml p<0.05). Conclusions: These results confirm the role of suPAR as a protein marker of MAGI and support the hypothesis that hypogonadism induces a state of inflammation in male accessory glands which is involved in male infertility. Moreover demonstrated that testosterone treatment probably exerts a positive effect on MAGI and infertility as documented by reduction of suPAR levels in hypogonadic treated patients.

Original languageEnglish
Pages (from-to)478-482
Number of pages5
JournalProtein and Peptide Letters
Volume25
Issue number5
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Urokinase Plasminogen Activator Receptors
Hypogonadism
Accessories
Inflammation
Testosterone
Semen
Plasmas
Immunosorbents
Lower Urinary Tract Symptoms
Control Groups
Male Infertility
Prostatic Hyperplasia
Therapeutics
Androgens
Assays
Infertility
Proteins
Enzyme-Linked Immunosorbent Assay

Keywords

  • Inflammation
  • MAGI
  • Male hypogonadism
  • Prostatitis
  • SuPAR
  • Testosterone replacement therapy

ASJC Scopus subject areas

  • Structural Biology
  • Biochemistry

Cite this

Seminal suPAR levels as marker of Abacterial male accessory gland inflammation in Hypogonadism. / Milardi, Domenico; Grande, Giuseppe; Autilio, Chiara; Mancini, Francesca; De Marinis, Laura; Marana, Riccardo; Zuppi, Cecilia; Urbani, Andrea; Pontecorvi, Alfredo; Baroni, Silvia.

In: Protein and Peptide Letters, Vol. 25, No. 5, 01.01.2018, p. 478-482.

Research output: Contribution to journalArticle

Milardi, Domenico ; Grande, Giuseppe ; Autilio, Chiara ; Mancini, Francesca ; De Marinis, Laura ; Marana, Riccardo ; Zuppi, Cecilia ; Urbani, Andrea ; Pontecorvi, Alfredo ; Baroni, Silvia. / Seminal suPAR levels as marker of Abacterial male accessory gland inflammation in Hypogonadism. In: Protein and Peptide Letters. 2018 ; Vol. 25, No. 5. pp. 478-482.
@article{5fb1538397d3474f91c34826c47941f1,
title = "Seminal suPAR levels as marker of Abacterial male accessory gland inflammation in Hypogonadism",
abstract = "Background: Recent evidences suggest that hypogonadism is an important risk factor for lower urinary tract symptoms and benign prostatic hyperplasia. Several papers have discussed the role of chronic inflammation in the development of BPH, which may be modulated by the hypogonadal state. Soluble Urokinase-type Plasminogen Activator Receptor (suPAR), known protein marker of systemic inflammation, can be assayed in the seminal plasma and represents a reliable and sensitive marker of inflammation for the Male Accessory Gland Inflammation (MAGI). Objective: The aim of this study has been to investigate if seminal suPAR is elevated in MAGI with hypogonadism and if suPAR represent a useful marker of abacterial inflammation in hypogonadism. Methods: We included in the study twenty male patients aged between 25 and 55 year-old with secondary postsurgical hypogonadism. The same patients were also evaluated after a 3-month of Testosterone Replacement Therapy (TRT), to evaluate the effect of androgen replacement therapy on suPAR. Ten fertile men have been enrolled as a control group in the protocol. SuPAR concentrations were assayed on seminal plasma using an Enzyme-Linked Immunosorbent Assay (ELISA) kit. Results: Hypogonadic patients presented significantly increased levels of seminal suPAR respect to controls (86.1±36.8 vs 55.2±20.0 ng/mL, p<0.05). TRT in hypogonadic patients has been associated with a significant reduction of suPAR levels as reported in the control group (50.9±22.91 vs 86.1±36.8 ng/ml p<0.05). Conclusions: These results confirm the role of suPAR as a protein marker of MAGI and support the hypothesis that hypogonadism induces a state of inflammation in male accessory glands which is involved in male infertility. Moreover demonstrated that testosterone treatment probably exerts a positive effect on MAGI and infertility as documented by reduction of suPAR levels in hypogonadic treated patients.",
keywords = "Inflammation, MAGI, Male hypogonadism, Prostatitis, SuPAR, Testosterone replacement therapy",
author = "Domenico Milardi and Giuseppe Grande and Chiara Autilio and Francesca Mancini and {De Marinis}, Laura and Riccardo Marana and Cecilia Zuppi and Andrea Urbani and Alfredo Pontecorvi and Silvia Baroni",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/0929866525666180418121421",
language = "English",
volume = "25",
pages = "478--482",
journal = "Protein and Peptide Letters",
issn = "0929-8665",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Seminal suPAR levels as marker of Abacterial male accessory gland inflammation in Hypogonadism

AU - Milardi, Domenico

AU - Grande, Giuseppe

AU - Autilio, Chiara

AU - Mancini, Francesca

AU - De Marinis, Laura

AU - Marana, Riccardo

AU - Zuppi, Cecilia

AU - Urbani, Andrea

AU - Pontecorvi, Alfredo

AU - Baroni, Silvia

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Recent evidences suggest that hypogonadism is an important risk factor for lower urinary tract symptoms and benign prostatic hyperplasia. Several papers have discussed the role of chronic inflammation in the development of BPH, which may be modulated by the hypogonadal state. Soluble Urokinase-type Plasminogen Activator Receptor (suPAR), known protein marker of systemic inflammation, can be assayed in the seminal plasma and represents a reliable and sensitive marker of inflammation for the Male Accessory Gland Inflammation (MAGI). Objective: The aim of this study has been to investigate if seminal suPAR is elevated in MAGI with hypogonadism and if suPAR represent a useful marker of abacterial inflammation in hypogonadism. Methods: We included in the study twenty male patients aged between 25 and 55 year-old with secondary postsurgical hypogonadism. The same patients were also evaluated after a 3-month of Testosterone Replacement Therapy (TRT), to evaluate the effect of androgen replacement therapy on suPAR. Ten fertile men have been enrolled as a control group in the protocol. SuPAR concentrations were assayed on seminal plasma using an Enzyme-Linked Immunosorbent Assay (ELISA) kit. Results: Hypogonadic patients presented significantly increased levels of seminal suPAR respect to controls (86.1±36.8 vs 55.2±20.0 ng/mL, p<0.05). TRT in hypogonadic patients has been associated with a significant reduction of suPAR levels as reported in the control group (50.9±22.91 vs 86.1±36.8 ng/ml p<0.05). Conclusions: These results confirm the role of suPAR as a protein marker of MAGI and support the hypothesis that hypogonadism induces a state of inflammation in male accessory glands which is involved in male infertility. Moreover demonstrated that testosterone treatment probably exerts a positive effect on MAGI and infertility as documented by reduction of suPAR levels in hypogonadic treated patients.

AB - Background: Recent evidences suggest that hypogonadism is an important risk factor for lower urinary tract symptoms and benign prostatic hyperplasia. Several papers have discussed the role of chronic inflammation in the development of BPH, which may be modulated by the hypogonadal state. Soluble Urokinase-type Plasminogen Activator Receptor (suPAR), known protein marker of systemic inflammation, can be assayed in the seminal plasma and represents a reliable and sensitive marker of inflammation for the Male Accessory Gland Inflammation (MAGI). Objective: The aim of this study has been to investigate if seminal suPAR is elevated in MAGI with hypogonadism and if suPAR represent a useful marker of abacterial inflammation in hypogonadism. Methods: We included in the study twenty male patients aged between 25 and 55 year-old with secondary postsurgical hypogonadism. The same patients were also evaluated after a 3-month of Testosterone Replacement Therapy (TRT), to evaluate the effect of androgen replacement therapy on suPAR. Ten fertile men have been enrolled as a control group in the protocol. SuPAR concentrations were assayed on seminal plasma using an Enzyme-Linked Immunosorbent Assay (ELISA) kit. Results: Hypogonadic patients presented significantly increased levels of seminal suPAR respect to controls (86.1±36.8 vs 55.2±20.0 ng/mL, p<0.05). TRT in hypogonadic patients has been associated with a significant reduction of suPAR levels as reported in the control group (50.9±22.91 vs 86.1±36.8 ng/ml p<0.05). Conclusions: These results confirm the role of suPAR as a protein marker of MAGI and support the hypothesis that hypogonadism induces a state of inflammation in male accessory glands which is involved in male infertility. Moreover demonstrated that testosterone treatment probably exerts a positive effect on MAGI and infertility as documented by reduction of suPAR levels in hypogonadic treated patients.

KW - Inflammation

KW - MAGI

KW - Male hypogonadism

KW - Prostatitis

KW - SuPAR

KW - Testosterone replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=85049599999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049599999&partnerID=8YFLogxK

U2 - 10.2174/0929866525666180418121421

DO - 10.2174/0929866525666180418121421

M3 - Article

C2 - 29667546

AN - SCOPUS:85049599999

VL - 25

SP - 478

EP - 482

JO - Protein and Peptide Letters

JF - Protein and Peptide Letters

SN - 0929-8665

IS - 5

ER -